Fundraising FoxSerda Therapeutics
1 known investors
Find your way into Serda Therapeutics
Sign up to see every warm intro you have to Serda Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Serda Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
SERDA Therapeutics is a clinical-stage biopharmaceutical company developing a prescription wound debridement therapy that uses a proprietary proteolytic enzyme to selectively digest necrotic tissue and eschar. Its lead candidate, SN514, targets burn wounds and chronic ulcers such as diabetic foot and venous leg ulcers.
Investors · 1
NLClisted by NLCAmsterdam
How we know: NLC's portfolio page · Not right? Tell us
Frequently asked questions
- What does Serda Therapeutics do?
- SERDA Therapeutics is a clinical-stage biopharmaceutical company developing a prescription wound debridement therapy that uses a proprietary proteolytic enzyme to selectively digest necrotic tissue and eschar. Its lead candidate, SN514, targets burn wounds and chronic ulcers such as diabetic foot and venous leg ulcers.
- Who are Serda Therapeutics's investors?
- Serda Therapeutics's investors include NLC.